A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy and safety of SAL0120 tablets in patients with uncontrolled essential hypertension who are receiving two or more lines of medication
Latest Information Update: 20 Mar 2026
At a glance
- Drugs SAL 0120 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Shenzhen Salubris Pharmaceuticals
Most Recent Events
- 20 Mar 2026 New trial record